3-Oxetanone → HCID 54761857、化合物
反応式
Cl.F[CH2:3][C:4]([C:8]1[O:12][N:11]=[C:10]([NH:13][C:14](=[O:38])[NH:15][C:16]2[CH:21]=[CH:20][C:19]([NH:22][C:23](=[O:37])[C:24]3[CH:29]=[CH:28][C:27]([O:30][CH:31]4[CH2:36][CH2:35][NH:34][CH2:33][CH2:32]4)=[CH:26][N:25]=3)=[CH:18][CH:17]=2)[CH:9]=1)([CH3:7])[CH2:5]F.[O:39]1[CH2:42]C(=O)[CH2:40]1>CC(C)=O>[C:4]([C:8]1[O:12][N:11]=[C:10]([NH:13][C:14](=[O:38])[NH:15][C:16]2[CH:17]=[CH:18][C:19]([NH:22][C:23](=[O:37])[C:24]3[CH:29]=[CH:28][C:27]([O:30][CH:31]4[CH2:32][CH2:33][N:34]([CH:35]5[CH2:42][O:39][CH2:40]5)[CH2:36]4)=[CH:26][N:25]=3)=[CH:20][CH:21]=2)[CH:9]=1)([CH3:3])([CH3:7])[CH3:5]参加物
4
実験手順
N-(4-(3-(5-tert-Butylisoxazol-3-yl)ureido)phenyl)-5-(1-(oxetan-3-yl)pyrrolidin-3-yloxy)picolinamide (77 mg, 73%) was prepared as a white powder using a procedure analogous to that described in Example 20, substituting N-(4-(3-(5-tert-butylisoxazol-3-yl)ureido)phenyl)-5-(pyrrolidin-3-yloxy)picolinamide hydrochloride from Step 2 of Example 25 for N-(4-(3-(5-(1,3-difluoro-2-methylpropan-2-yl)isoxazol-3-yl)ureido)phenyl)-5-(piperidin-4-yloxy)picolinamide hydrochloride, and oxetan-3-one for acetone used in Example 20. LC-MS (ESI) m/z 521 (M+H)+.